Filana Therapeutics
FLNA
85 hedge funds and large institutions have $15.1M invested in Filana Therapeutics in 2026 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 21 increasing their positions, 33 reducing their positions, and 22 closing their positions.
56% more call options, than puts
Call options by funds: $635K | Put options by funds: $407K
2% less ownership
Funds ownership: 28.25% → 26.25% (-2%)
16% less funds holding
Funds holding: 101 → 85 (-16)
35% less capital invested
Capital invested by funds: $23.1M → $15.1M (-$7.97M)
36% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 33
64% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$894K |
| 2 |
Squarepoint
New York
|
+$454K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$107K |
| 4 |
Renaissance Technologies
New York
|
+$89.5K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$73.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$591K |
| 2 |
Two Sigma Investments
New York
|
-$395K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$353K |
| 4 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$320K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$305K |
FLNA Hedge Fund Activity: Q2 2026 in Review
85 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2026, worth a combined $15.1M — down 35% from $23.1M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of FLNA and 8 opened new positions — a net loss of 14 holders — while 33 trimmed existing stakes and 21 added.
The largest buyer was Goldman Sachs, adding an estimated $894K. The largest seller was Marshall Wace, cutting an estimated $591K.
- 85 institutional investors held Filana Therapeutics (FLNA) as of Q2 2026, down from 101 in Q1 2026.
- Funds reported $15.1M of Filana Therapeutics stock for Q2 2026, down 35% quarter-over-quarter.
- 8 funds opened new Filana Therapeutics positions in Q2 2026 and 22 closed out, a net change of -14 holders.
- The largest Filana Therapeutics buyer in Q2 2026 was Goldman Sachs, an estimated $894K added.
- The largest Filana Therapeutics seller in Q2 2026 was Marshall Wace, an estimated $591K sold.
Based on aggregated 13F filings for Q2 2026.